Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Development of a YB-1 dependent Virotherapy for the treatment of non-muscle invasive bladder cancer

Funder: German Research Foundation

Funding period
0
Funding amount
Abstract
Bladder cancer is the second most tumor of the urinary tract with ca 28.000 newly diagnosed cases per year in Germany. At diagnosis, around 75% of tumors present as non-muscle invasive disease (NMIBC) that is characterized with a low progression rate but with recurrence rates after therapy of 80% within 5 years. New therapeutic strategies are therefore necessary. The aim of this proposal ist he preclinical establishment of a virotherapy for patients suffering from NMIBC. Virotherapy and in particular the use of oncolytic adenoviruses (OAV) is a relatively novel therapeutic strategy that is currently tested in clinical trials mostly in tumor entities different from bladder cancer. We developed a virotherapy that is dependent on the expression of the cellular oncogen YB-1 that has been shown to be expressed in bladder cancer. In this proposal we will focus on three aspects. First, we will analyze expression level of YB-1 as well as molecular determinants that are involved in the regulation of expression patterns of YB-1 to allow prognostic information on therapy response. The anti-tumor activity of the virus not only depends on the direct lytic properties in cancer cells but also in its capacity to stimulate the immune system. Secreted YB-1 has been shown to simulate the immune system. We will analyze in detail the effect of virus induced secreted YB-1 on the stimulation of the immune system. Thirdly, we will analyze use of the virus in different in vivo systems. In a chicken chorioallantoic membrane model (CAM) we will characterize the oncolytic capacity of the virus. The underlying molecular mechanism of the immune stimulating activity will be analyzed in a SCID-Beige-mouse model and the efficacy of an instillation approach on tumor growth will be analyzed in an immune-incompetent nude mouse model.
Similar projects All >
Sorted by: Start Date
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2020 - 2021
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Alpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision

European Commission

USD 2,452,885
2020 - 2022

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Biotechnology

  • RCDC

    Gene Therapy

  • RCDC

    Cancer

  • RCDC

    Genetics

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science